128 related articles for article (PubMed ID: 11272373)
1. Low-energy 103Pd gamma (X-ray) source for vascular brachytherapy.
Sioshansi P; Bricault RJ
Cardiovasc Radiat Med; 1999; 1(3):278-87. PubMed ID: 11272373
[TBL] [Abstract][Full Text] [Related]
2. Calculation of the 3-D dose distribution surrounding a 103Pd stent.
McLemore LB; Horton JL; Antolak JA
Cardiovasc Radiat Med; 2001; 2(3):181-90. PubMed ID: 11786325
[TBL] [Abstract][Full Text] [Related]
3. Accuracy assessment of the superposition principle for evaluating dose distributions of elongated and curved 103Pd and 192Ir brachytherapy sources.
Bannon EA; Yang Y; Rivard MJ
Med Phys; 2011 Jun; 38(6):2957-63. PubMed ID: 21815369
[TBL] [Abstract][Full Text] [Related]
4. Beta versus gamma for catheter-based intravascular brachytherapy: dosimetric perspectives in the presence of metallic stents and calcified plaques.
Li XA; Wang R; Yu C; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):1043-9. PubMed ID: 10705028
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.
Bohm TD; DeLuca PM; DeWerd LA
Med Phys; 2003 Apr; 30(4):701-11. PubMed ID: 12722822
[TBL] [Abstract][Full Text] [Related]
6. Two-dimensional dosimetry in the near field of the model 200 103Pd source for interstitial brachytherapy implants using a thermoluminescent sheet.
Iwata K; Yue NJ; Nath R
Phys Med Biol; 2004 Sep; 49(17):4049-63. PubMed ID: 15470922
[TBL] [Abstract][Full Text] [Related]
7. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
8. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
9. On the use of apparent activity (Aapp) for treatment planning of 125I and 103Pd interstitial brachytherapy sources: recommendations of the American Association of Physicists in Medicine radiation therapy committee subcommittee on low-energy brachytherapy source dosimetry.
Williamson JF; Coursey BM; DeWerd LA; Hanson WF; Nath R; Rivard MJ; Ibbott G
Med Phys; 1999 Dec; 26(12):2529-30. PubMed ID: 10619235
[No Abstract] [Full Text] [Related]
10. Some treatment planning considerations for 103Pd and 125I permanent interstitial implants.
Nath R; Meigooni AS; Melillo A
Int J Radiat Oncol Biol Phys; 1992; 22(5):1131-8. PubMed ID: 1555965
[TBL] [Abstract][Full Text] [Related]
11. Monte Carlo calculation of dosimetry parameters for the IR08-103Pd brachytherapy source.
Saidi P; Sadeghi M; Shirazi A; Tenreiro C
Med Phys; 2010 Jun; 37(6):2509-15. PubMed ID: 20632562
[TBL] [Abstract][Full Text] [Related]
12. Experimental determination of dosimetric characterization of a newly designed encapsulated interstitial brachytherapy source of 103Pd-model Pd-1.
Nath R; Yue N; Roa E
Med Phys; 2002 Oct; 29(10):2433-4. PubMed ID: 12408318
[TBL] [Abstract][Full Text] [Related]
13. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription.
Williamson JF; Coursey BM; DeWerd LA; Hanson WF; Nath R; Rivard MJ; Ibbott G
Med Phys; 2000 Apr; 27(4):634-42. PubMed ID: 10798683
[TBL] [Abstract][Full Text] [Related]
14. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
[TBL] [Abstract][Full Text] [Related]
15. Dose rate constants for 125I, 103Pd, 192Ir and 169Yb brachytherapy sources: an EGS4 Monte Carlo study.
Mainegra E; Capote R; López E
Phys Med Biol; 1998 Jun; 43(6):1557-66. PubMed ID: 9651025
[TBL] [Abstract][Full Text] [Related]
16. Monte Carlo calculations and experimental measurements of dosimetric parameters of the IRA-103Pd brachytherapy source.
Sadeghi M; Raisali G; Hosseini SH; Shavar A
Med Phys; 2008 Apr; 35(4):1288-94. PubMed ID: 18491522
[TBL] [Abstract][Full Text] [Related]
17. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
Yue N; Chen Z; Nath R
Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
[TBL] [Abstract][Full Text] [Related]
18. Theoretical analysis of microdosimetric spectra and cluster formation for 103Pd and 125I photon emitters.
Reniers B; Vynckier S; Verhaegen F
Phys Med Biol; 2004 Aug; 49(16):3781-95. PubMed ID: 15446805
[TBL] [Abstract][Full Text] [Related]
19. Approaches to calculating AAPM TG-43 brachytherapy dosimetry parameters for 137Cs, 125I, 192Ir, 103Pd, and 169Yb sources.
Melhus CS; Rivard MJ
Med Phys; 2006 Jun; 33(6):1729-37. PubMed ID: 16872080
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric characteristics of the bests double-wall 103Pd brachytherapy source.
Meigooni AS; Bharucha Z; Yoe-Sein M; Sowards K
Med Phys; 2001 Dec; 28(12):2568-75. PubMed ID: 11797962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
